The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer
Official Title: Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer
Study ID: NCT00789581
Brief Summary: This is a randomized, Phase III, open-label, multicenter study.
Detailed Description: Patients will be randomized in a 1:1 ratio to receive one of two different treatment arms. Patients in treatment arm 1 will receive AC followed by ixabepilone. Patients in treatment arm 2 will receive AC followed by weekly paclitaxel.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Northeast Alabama Regional Medical Center, Anniston, Alabama, United States
Cancer Center of Huntsville, Huntsville, Alabama, United States
Clearview Cancer Institute, Huntsville, Alabama, United States
University of Southern Alabama, Mobile, Alabama, United States
Northeast Arkansas Clinic, Jonesboro, Arkansas, United States
Wilshire Oncology Medical Group, La Verne, California, United States
New Hope Cancer and Research Institute, Pomona, California, United States
Eastern Connecticut Hematology Oncology, Norwich, Connecticut, United States
Aventura Medical Center, Aventura, Florida, United States
Lynn Cancer Institute, Boca Raton, Florida, United States
Florida Cancer Care, Davie, Florida, United States
Holy Cross Hospital, Fort Lauderdale, Florida, United States
Florida Cancer Specialists, Fort Myers, Florida, United States
Memorial Regional Cancer Center, Hollywood, Florida, United States
Integrated Community Oncology Network, Jacksonville, Florida, United States
Watson Clinic Center for Cancer Care and Research, Lakeland, Florida, United States
Space Coast Medical Associates, Titusville, Florida, United States
Piedmont Healthcare, Atlanta, Georgia, United States
Emory/Winship Cancer Institute, Atlanta, Georgia, United States
Augusta Oncology Associates, Augusta, Georgia, United States
Medical Oncology Associates of Augusta, Augusta, Georgia, United States
Medical College of Georgia Cancer Specialists, Augusta, Georgia, United States
Northeast Georgia Medical Center, Gainesville, Georgia, United States
Suburban Hem Onc, Lawrenceville, Georgia, United States
Mid-Illinois Hematology & Oncology, Normal, Illinois, United States
Hematology Oncology of the North Shore, Skokie, Illinois, United States
Oncology Hematology Associates of SW Indiana, Evansville, Indiana, United States
Hematology Oncology of Indiana, Indianapolis, Indiana, United States
Providence Medical Group, Terre Haute, Indiana, United States
Kansas City Cancer Centers, Overland Park, Kansas, United States
Cotton O'Neil Cancer Center, Topeka, Kansas, United States
Consultants in Blood Disorders and Cancer, Louisville, Kentucky, United States
Baton Rouge General Medical Center, Baton Rouge, Louisiana, United States
Mercy Hospital, Portland, Maine, United States
Weinberg Cancer Institute at Franklin Square, Baltimore, Maryland, United States
Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
Fallon Clinic, Worcester, Massachusetts, United States
Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, United States
Fairview Medical Oncology Clinic, Edina, Minnesota, United States
St. Louis Cancer Care, Chesterfield, Missouri, United States
Research Medical Center, Kansas City, Missouri, United States
St. John's Clinic, Springfield, Missouri, United States
Methodist Cancer Center, Omaha, Nebraska, United States
St. Clare's Hospital Oncology and Hematology, Denville, New Jersey, United States
Hematology Oncology Associates of Northern NJ, Morristown, New Jersey, United States
Southern Oncology and Hematology, Vineland, New Jersey, United States
New Mexico Oncology Hematology Consultants, Albuquerque, New Mexico, United States
Alamance Regional Medical Center, Burlington, North Carolina, United States
Oncology Hematology Care, Cincinnati, Ohio, United States
Mid Ohio Oncology/Hematology, Inc./ The Mark H. Zangmeister Center, Columbus, Ohio, United States
Hematology/Oncology Inc, Elyria, Ohio, United States
Hickman Cancer Center (Flower Hospital), Sylvania, Ohio, United States
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Bux-Mont Oncology, Fox Chase Cancer Center, Rockledge, Pennsylvania, United States
Medical University of South Carolina, Charleston, South Carolina, United States
South Carolina Oncology Associates, PA, Columbia, South Carolina, United States
Lowcountry Hematology Oncology, Mount Pleasant, South Carolina, United States
Coastal Cancer Center, Myrtle Beach, South Carolina, United States
Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States
Associates in Hematology Oncology, Chattanooga, Tennessee, United States
Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
Family Cancer Center, Collierville, Tennessee, United States
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Coastal Bend Cancer Center, Corpus Christi, Texas, United States
Center for Cancer and Blood Disorders, Fort Worth, Texas, United States
Medical Oncology Methodist Hospital, Houston, Texas, United States
South Texas Oncology and Hematology, San Antonio, Texas, United States
Peninsula Cancer Institute, Newport News, Virginia, United States
Virginia Cancer Institute, Richmond, Virginia, United States
San Juan Hospital, San Juan, , Puerto Rico
Name: Denise A Yardley, M.D.
Affiliation: SCRI Development Innovations, LLC
Role: STUDY_CHAIR